March 5, 2019

HEAL Partnership Committee Meeting

8:00 a.m.
Welcome, Introductions, and Review of Agenda
Francis Collins, M.D., Ph.D., Director, National Institutes of Health (NIH)

8:15 a.m.
Conflicts of Interest Declarations
Lawrence Tabak, D.D.S., Ph.D., Principal Deputy Director, NIH

8:25 a.m
Role of the HEAL Partnership Committee in the HEAL Initiative
Rebecca Baker, Ph.D., Director, HEAL Initiative, Office of the Director, NIH

8:35 a.m.
Review of NIH Programs for Developing and Testing Pain Treatments
Walter Koroshetz, M.D., Director, National Institute of Neurological Disorders and Stroke (NINDS)

  • EPPIC NET – How it will work
  • NIH Solicitation, Review, and Awards Process

9:20 a.m
Challenges of the Development of Pain Therapies & Intersection with HEAL 
Judith Paice, Ph.D., Director of the Cancer Pain Program, Northwestern University

Regulatory considerations for evaluation and approval of pain medications 
Patrizia Cavazzoni, M.D., Deputy Director for Operations at Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration

Industry considerations for development of assets 
Ken Verburg, Ph.D., Senior Vice President and Medicine Team Leader, Pfizer

Medical device perspective 
Ashley Wittorf, Executive Director of AdvaMed Accel, AdvaMed

Perspective of people with pain
Christin Veasley, Cofounder and Director, Chronic Pain Research Alliance

10:00 a.m.

10:30 a.m.
Panel Discussion – Q&A
Judith Paice – Moderator
Patrizia Cavazzoni, Ken Verburg, Ashley Wittorf, Christin Veasley

11:00 a.m.
Considerations for the Review of Assets for EPPIC Net 
Amir Tamiz, Ph.D., Director, Division of Translational Research, NINDS

  • Discuss business and scientific considerations
  • Examine special considerations for biologics, small molecules, and devices

12:30 p.m.

1:15 p.m.
Continued - Considerations for the Review of Assets for EPPIC Net

3:00 p.m.
Summary of the Day’s Discussion
David Wholley, Foundation for the NIH

3:10 p.m.
Next Steps 
Rebecca Baker, Ph.D., Director, HEAL Initiative, Office of the Director, NIH

3:20 p.m.
Final Remarks and Closing
Walter Koroshetz, M.D., Director, NINDS

This page last reviewed on April 3, 2019